Skip to content

Emil Deleuran Poulsen

4 papers in the library · 99 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Journal of Psychopharmacology February 28, 2025 Dea Siggaard Stenbæk, Emil Deleuran Poulsen, Marie Katrine Klose Nielsen et al. 15 citations

Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of a single dose have not been investigated. Aims: To investigate the pharmacokinetics, feasibility, safety and efficacy of single-dose psilocybin therapy in AUD. Methods: This...

DOI: 10.1177/02698811251319457 (opens in new tab) Alcohol use disorder Psilocybin Craving Pharmacokinetics +5

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study

Research Square August 23, 2024 Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell et al. 1 citation

Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psilocybin therapy in AUD. Methods This...

DOI: 10.21203/rs.3.rs-4947184/v1 (opens in new tab) Full text (opens in new tab) Psilocybin Alcohol use disorder Pharmacokinetics Pharmacology

Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics

Journal of Psychopharmacology November 16, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred 31 citations

Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a...

DOI: 10.1177/02698811231200019 (opens in new tab) Full text (opens in new tab) Ayahuasca Psilocybin Lysergic acid diethylamide Hallucinogen +6

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Journal of Psychopharmacology July 1, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred et al. 52 citations

Background: The classical psychedelics, psilocybin, peyote, ayahuasca/ N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical...

DOI: 10.1177/02698811231180276 (opens in new tab) Randomized controlled trial Clinical trial Medline Clinical psychology